Company profile: Editas Medicine
1.1 - Company Overview
Company description
- Provider of clinical-stage genome editing medicines and a CRISPR gene editing platform, including Reni-cel for severe sickle cell disease and transfusion-dependent beta thalassemia (editing CD34+ cells at HBG1/HBG2 promoters), EDIT-101 for Leber congenital amaurosis 10 (repairing the IVS26 CEP290 allele), and ex vivo and in vivo gene editing medicines for ocular, blood diseases, and cancer.
Products and services
- CRISPR Gene Editing Platform: A CRISPR-based framework that utilizes gene editing to develop medicines for ocular, blood diseases, and cancer, supporting therapeutic development across these disease areas
- EDIT-101: An allele-specific gene editing medicine engineered to treat blindness due to Leber congenital amaurosis 10 by repairing the IVS26 CEP290 mutant allele
- Reni-Cel: A promoter-targeted gene editing medicine under investigation for severe sickle cell disease and transfusion-dependent beta thalassemia, editing CD34+ cells at the HBG1 and HBG2 promoters
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Editas Medicine
Regulus Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-based therapeutics designed to inhibit dysregulated microRNA targets for genetically based orphan diseases, particularly orphan kidney diseases. Portfolio includes RGLS8429, a next-generation anti-miR-17 in Phase 1b for autosomal dominant polycystic kidney disease (ADPKD), supported by ongoing clinical trials to evaluate efficacy and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regulus Therapeutics company profile →
Prevail Therapeutics
HQ: United States
Website
- Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevail Therapeutics company profile →
Nanogenics
HQ: United Kingdom
Website
- Description: Provider of research-based biotechnology developing artificial viruses for gene therapy. Products include LipTide, a synthetic peptide nanoparticle that mimics natural viruses for targeted RNA delivery to various cell types with low toxicity and repeat dosing, and ECP-105, a glaucoma therapy enhancing trabeculectomy by increasing bleb survival and reducing scarring with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanogenics company profile →
Beam Therapeutics
HQ: United States
Website
- Description: Provider of precision genetic medicines using base editing, including BEAM-101 for sickle cell disease; BEAM-201, an anti-CD7 CAR-T for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; and liver-targeting LNPs BEAM-301 and BEAM-302 to correct the R83C mutation in Glycogen Storage Disease Type 1a and the PiZ allele in severe Alpha-1 antitrypsin deficiency, plus base editing delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beam Therapeutics company profile →
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elsie Biotechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Editas Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Editas Medicine
2.2 - Growth funds investing in similar companies to Editas Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Editas Medicine
4.2 - Public trading comparable groups for Editas Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →